[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc announced on 29 September 2025 that it purchased 1,996,340 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. Trades executed on the London Stock Exchange/CBOE (UK)/CXE on 26 September 2025 show prices reported between £325.1000 and £328.7000 with an average of £327.6614. The Company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 40,904,443 are treasury shares, leaving 8,911,449,205 ordinary shares with voting rights. A full trade breakdown is available via the provided RNS link and the Company website.

Positive

• Executed second-tranche buyback of 1,996,340 shares under the programme announced 31 July 2025
• Shares will be held as treasury shares, and the company published updated registered capital and voting share figures
• Transparent disclosure with full trade breakdown available and compliance with Market Abuse Regulation reporting

Negative

• None.

Insights

Financial Analyst

TL;DR: Buyback executed as planned; quantity is small relative to total shares outstanding, modestly reducing voting shares.

The announced purchase of 1,996,340 shares demonstrates active execution of Haleon's share buyback programme. The reported trade prices (range £325.10–£328.70; average £327.6614) show execution in a narrow band, and the shares will be held in treasury. Given the company's total registered capital and treasury holdings, this tranche represents a very small percentage of outstanding shares, so the immediate impact on EPS or voting control is limited. Disclosure follows Market Abuse Regulation requirements with a detailed trade breakdown available.

Corporate Governance Expert

TL;DR: Proper disclosure and treasury treatment maintained; shareholders can use updated voting figure for regulatory notifications.

Haleon has disclosed the buyback and stated intent to hold the shares as treasury, which is a standard corporate action. The company provided the post-settlement figures for registered capital and voting shares, enabling shareholders to assess notification thresholds under FCA rules. The announcement includes a link to the full individual trade breakdown to comply with Article 5(1)(b) of the Market Abuse Regulation as applied in the UK.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	29 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

29 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,996,340 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	26 September 2025	26 September 2025	26 September 2025
Number of Shares purchased:	1,996,340	-	-
Highest price paid per Share (p):	328.7000	-	-
Lowest price paid per Share (p):	325.1000	-	-
Volume weighted average price paid per Share (p):	327.6614	-	-

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 40,904,443 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,911,449,205 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/0863B_1-2025-9-26.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 29, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many shares did Haleon (HLN) buy back on 26 September 2025?

Haleon purchased 1,996,340 ordinary shares under the second tranche of its buyback programme.

At what prices were the HLN shares purchased?

Reported trade prices ranged between £325.1000 and £328.7000 with an average of £327.6614.

Will the repurchased HLN shares be cancelled or held as treasury?

The Company intends to hold the purchased shares as treasury shares.

What is Haleon's registered share capital and number of voting shares after settlement?

Registered share capital is 8,952,353,648 ordinary shares; 40,904,443 are held as treasury, leaving 8,911,449,205 voting shares.

Where can I find the full breakdown of individual trades?

A full breakdown is available at the RNS link provided in the announcement: http://www.rns-pdf.londonstockexchange.com/rns/0863B_1-2025-9-26.pdf and on www.haleon.com/investors.